Cerevance has achieved Phase II trial success with its drug candidate reducing the time Parkinson’s disease patients spent in ‘Off time’ where symptoms recur despite medication.
CVN424 is the privately-held company’s lead candidate, and after producing encouraging safety, efficacy results and side-effect profile results, it now...